🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

1/5 Excited to activate this week our fourth clinical trial designed for #RenalMedullaryCarcinoma (RMC). It will also separately enroll patients with epithelioid sarcoma, another rare but deadly cancer defined by loss of the SMARCB1 tumor suppressor: clinicaltrials.gov/study/NCT06444…

We tested the feasibility and immunogenicity of a personalized neoantigen vaccine + PD-L1 blockade in #bladdercancer including the adjuvant setting. nature.com/articles/s4301… Jon Anker, MD, PhD Bhardwaj Lab UroToday.com Uromigos The Tisch Cancer Institute Dr. Bishoy M. Faltas Nature Cancer Bladder Cancer Advocacy Network

⚡️ FDA analysis in metastatic RCC: Cytoreductive nephrectomy before ICI + VEGFi was associated with: ✔️ Longer OS (46 vs. 28 months) ✔️ Improved PFS and ORR Retrospective, hypothesis-generating—but clinically relevant. academic.oup.com/jnci/article/1… #KidneyCancer #Immunotherapy

An amazing group of colleagues for all interested in the latest on #RCC!

*** GUPS Virtual Education Series – June 2025 Event*** When: June 6, 2025 12:00 PM Eastern Time (US and Canada) Topic: Management of metastatic ‘clear cell’ versus ‘non-clear cell’ renal cell carcinoma Registration now open: us02web.zoom.us/webinar/regist…

Dr. Libby Wulff is GU med onc and palliative care expert who inspires me in her communication and shares how she approaches patient centered care. 🧡 My favorite takeaway: come with curiosity to understand what matters most. 🌟 GU Oncology Now #GUonc #PalliativeCare

Ab#4514 ASCO #ASCO25 by Naomi Haas👉bit.ly/44KiA7o👉5-yr f/u results of KEYNOTE-564 in pts w/ ccRCC #kidneycancer 👉Benefits w/ adjuvant pembro over placebo maintained (DFS HR 0.71 & OS HR 0.66)👇Toni Choueiri, MD OncoAlert UroToday.com KidneyCAN

Ab#4506 ASCO #ASCO25 by Toni Choueiri, MD👉bit.ly/3H57gZC👉Results from Ph 1 ARC-20 study #kidneycancer👉Casdatifan + Cabo has promising activity (manageable AEs) in pts w/ previously treated RCC👇#AlexandraDrakaki OncoAlert UroToday.com @KidneyCAN Kidney Cancer

Ab#4501 ASCO #ASCO25 by @Jcensits Marinos Tsiatas👉bit.ly/44SqITu👉Ave+SG vs Ave as 1L maintenance in pts w/ aUC #bladdercancer👉Median PFS improved w/ combo (11.2 vs 3.8 mo)👇#BegonaValderrama OncoAlert UroToday.com Uromigos Bladder Cancer Advocacy Network

Ab#4516 ASCO #ASCO25 by Tian Zhang, MD, MHS 👉bit.ly/4k7p5Wv👉Alliance for Clinical Trials in Oncology Ph 3 PDIGREE trial 👉 ipi-nivo induction (f/ued by nivo, cabo or nivo-cabo in mccRCC #kidneycancer 👉Initial outcomes with induction ipi-nivo👇Toni Choueiri, MD OncoAlert UroToday.com @KidneyCAN

Ab#5015 ASCO #ASCO25 by Dr Andrew Parsonson 👉bit.ly/43DX82R👉Ph1/2 study of novel B7-H3-targeting ADC (DB 1311/BNT324) in CRPC #prostatecancer 👉Encouraging efficacy (unconfirmed ORR 27.9%) & manageable safety👇Mark Stein OncoAlert UroToday.com PCF Science

Ab#4503 ASCO #ASCO25 by Tom Powles👉bit.ly/3ShB5sl👉ctDNA analysis in Ph 3 NIAGARA trial #bladdercancer👉Presence of ctDNA before surgery was associated w/ non-pCR👇Matt Galsky OncoAlert UroToday.com Uromigos Bladder Cancer Advocacy Network

Ab#4510 ASCO #ASCO25 by Sumanta K. Pal, MD, FASCO 👉 bit.ly/3YYrtGH 👉Genomic profiling data from ph3 IMmotion010 trial of adj atezo in pts w/ RCC #kidneycancer 👉Serum KIM-1 remains the most robust predictor of outcome w/ atezo👇Brian Rini, MD OncoAlert UroToday.com KidneyCAN Uromigos

T-7 days until #ASCO25! Can’t wait for updates on 🔬advancements in #GUonc and 🚀new #clinicaltrials. 💙💥 More than 6,000 abstracts = endless opportunities to learn, connect, and be inspired. Let’s go! 👏🧬 #OncoTwitter #KidneyCancer #BladderCancer #ProstateCancer

Ab#4528 ASCO #ASCO25 by #ZacharyYochum👉bit.ly/4kwsApi👉6-month TTF is predictive of 18-month OS in pts w/ mRCC receiving ICIs #kidneycancer 👉6-month TTF may be a promising intermediate endpoint for OS👇Daniel Heng Toni Choueiri, MD OncoAlert UroToday.com @KidneyCAN

The #ASCO25 #OncoAlertTOP10 Abstracts in #GUOncology These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸 #ProstateCancer #BladderCancer #kidneyCancer ⭐Abs 4518 SURE-02: NEOADJUVANT SACITUZUMAB GOVITECAN PLUS

Lots of excitement around CAR T in solid tumors, can’t wait to see the updated data at #ASCO25! #Immunotherapy #OncoTwitter 🔥🧬💥

Love that so many #GUonc experts are fired up about different trials 🔬💥 Can’t wait to see colleagues and hear what’s new and exciting for our patients with bladder, kidney, and prostate cancer 💪🧬 #ASCO25 #BladderCancer #KidneyCancer #ProstateCancer

1/2 ctDNA data for durvalumab+NAC in MIBC from NIAGARA #ASCO25. 57%,22%,9% of pts are ctDNA +ve at baseline/post NAC/post surgery. Poor outcomes for cDNA+ve occur at each time point (HR 0.4,0.3,0.1 respectively). Chemo cleared the ctDNA in most pts & was ⬆️13% with durvalumab

💊 Watch Tian Zhang, MD, MHS discuss the #PDIGREE trial on first-line ipi/nivo for patients with #mccRCC at ASCO #ASCO25: guoncologynow.com/post/pdigree-n… 🎬 Dr. Zhang comments on the differential response patterns that might inform early identification of non-responders.